Top Markets
#1 DogBull DogBull +107.72%
#2 Siacoin Siacoin +53.43%
#3 ADO Protocol ADO Protocol +52.14%
#4 The Bitcoin Bull The Bitcoin Bull +40.37%
#5 MarsCoin MarsCoin +40.06%
#6 Ontology Gas Ontology Gas +22.96%
#7 Falcon Finance Falcon Finance +20.18%
#8 UnifAI Network UnifAI Network +19.65%
#9 Nockchain Nockchain +19.53%
#10 Apertum Apertum +18.08%
Coin of the day
DogBull DogBull
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Jiangsu Recbio Technology Co., Ltd. Jiangsu Recbio Technology Co., Ltd.

Jiangsu Recbio Technology Co., Ltd.

2179
Classement en actions #15662
Jiangsu Recbio Technology Co., Ltd. operates as a biotechnology company... Jiangsu Recbio Technology Co., Ltd. operates as a biotechnology company primarily engaged in the pioneering research, development, and eventual market introduction of subunit vaccines throughout the People's Republic of China. A significant portion of its pipeline is dedicated to combating human papillomavirus (HPV)-related diseases, including cervical cancer and genital warts. Its most advanced candidate, REC603, is a recombinant 9-valent HPV vaccine currently undergoing Phase III clinical trials. Additionally, two bivalent HPV vaccines, REC601 and REC602, are progressing through Phase I trials. Further early-stage development includes the quadrivalent REC604a and 9-valent REC604b recombinant HPV vaccines, both in preclinical stages. Beyond HPV, the company boasts a diverse pipeline addressing other infectious diseases. Its COVID-19 efforts include ReCOV, a recombinant vaccine candidate in Phase II/III trials, and the preclinical messenger RNA (mRNA) candidate, R520A. Other preclinical projects target various conditions, such as the recombinant shingles vaccine REC610, the virus-vectored adult tuberculosis vaccine REC607, and its recombinant counterpart REC606. Also in preclinical development are the recombinant quadrivalent influenza vaccine REC617 and the recombinant quadrivalent hand-foot-mouth disease vaccine REC605. Established in 2011, Recbio Technology maintains its headquarters in Taizhou, People's Republic of China.
Prix de l'action
$0.63963115
Dernière synchronisation: 2026-08-26
Capitalisation boursière
$339.16M
Changement (1 jour)
0.00%
Changement (1 an)
-35.23%
Pays
CN
Échange Jiangsu Recbio Technology Co., Ltd. (2179)

Catégorie

Healthcare
Nombre d'actions en circulation pour Jiangsu Recbio Technology Co., Ltd. (2179)
Nombre d'actions en circulation au September 2026: 0
Selon les derniers rapports financiers et le cours de l'action de Jiangsu Recbio Technology Co., Ltd., le nombre actuel d'actions en circulation est de 0. À la fin de September 2026, l'entreprise avait 0 actions en circulation. Le nombre d'actions en circulation est généralement affecté par les divisions d'actions et les rachats d'actions.
Historique des actions en circulation de Jiangsu Recbio Technology Co., Ltd. (2179) de 2026 à 2026
Actions en circulation à la fin de chaque année
Année Actions en circulation Changez
Pas assez de données pour les dates fournies.
Actions en circulation pour des entreprises similaires ou concurrentes
Entreprise Actions en circulation Différence Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 253.90M -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 62.19M -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 396.00M -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 478.91M -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH